CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
| CalAmp Corp. (NASDAQ: CAMP) | Delayed: 3.96 +0.06 (1.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.90 | 52 Week High | $21.34 | |||
| Open | $3.87 | 52 Week Low | $12.13 | |||
| Day High | $4.01 | P/E | 2.98 | |||
| Day Low | $3.78 | EPS | $1.33 | |||
| Volume | 137,898 | |||||
